Posts

SHEPHERD THERAPEUTICS APPOINTS CMO, COO, AND STRATEGIC RESEARCH ANALYST

For Immediate Release

Contact:
Lacie Randall
Chief Creative Officer
lacie@shepherd.bio

SHEPHERD THERAPEUTICS APPOINTS CMO, COO, AND STRATEGIC RESEARCH ANALYST
Mission-Driven Biotech Strengthens Resources to Cure Rare Cancers

CAMBRIDGE, MA— December 14, 2016 — SHEPHERD Therapeutics, a life sciences company founded to cure rare cancers, today announced the appointments of Abby Reiner, Elizabeth Hostetter, and Jon Goetz to serve as Chief Marketing and Business Development Officer, Chief Operating Officer, and Strategic Research Analyst, respectively. “I am very excited to welcome Abby, Elizabeth, and Jon to the Shepherd team,” said David Hysong, patient, founder, and CEO of Shepherd. “These three individuals exemplify our desire to create a diverse team that brings a wide array of skills and experiences to our work. I am confident that Abby, Elizabeth, and Jon will each bring a unique perspective to our team dynamic and contribute profoundly to cure rare cancers.”

“I was really motivated by David’s story. His and the countless others’ I’ve heard since joining SHEPHERD are so powerful that if my talents can contribute to SHEPHERD’s mission to cure rare cancers, I’m in,” said Ms. Reiner. “SHEPHERD also has a world class team of experts of which I’m thrilled and humbled to be a part.”

“I am thrilled to be joining SHEPHERD at this pivotal moment,” said Ms. Hostetter. “David has been incredibly thoughtful in putting this team together. We share an energized commitment to change the outlook for patients with rare cancer and, in a few short months, have made extraordinary progress towards that goal. We are moving into the new year with an array of dynamic projects and I look forward to driving the momentum forward into the next phase of growth for SHEPHERD.”

“Although my experience lies in education, the mission of SHEPHERD embodies my passion in cultivating the wellbeing and personal flourishing of all people, regardless of situation,” said Mr. Goetz. “Health, like education, is a fundamental human right and I am excited to support Shepherd’s work through research and collaboration with the rest of the team.”

About Abby Reiner
Abby Reiner comes to SHEPHERD with a wealth of branding experience gained through work with the Wounded Warrior Project, PGA Tour, and Nike Golf Learning Centers. In her 10 years with the Wounded Warrior Project, Ms. Reiner established the brand architecture, visual brand assets, physical presence, and tangible brand experiences. Ms. Reiner led her team at Wounded Warrior in a 10-year anniversary campaign that encompassed a documentary film series picked up by MSNBC and Netflix. Ms. Reiner has been published by the Journal of Brand Strategy for her work in nonprofit brand protection and holds a B.S. in Marketing from Arizona State University.

About Elizabeth Hostetter
Prior to SHEPHERD, Elizabeth Hostetter worked as a consultant at Bain & Company where she advised companies across sectors to grow profitably, optimize costs and launch commercial products. Ms. Hostetter has experience in healthcare investment banking for Goldman Sachs and scientific research at the Broad Institute of MIT and Harvard. While completing her Master’s Studies in Business, Ms. Hostetter worked at Third Rock Ventures, a life sciences venture capital firm. Ms. Hostetter holds a B.A. in Human Biology from Stanford University and an M.B.A. from Harvard Business School.

About Jon Goetz
Jon Goetz joins SHEPHERD with a passion for research and instruction. As an undergraduate, Mr. Goetz worked with Breakthrough Collaborative, a national nonprofit focused on increasing academic opportunity for highly motivated, underserved students. Mr. Goetz holds an A.B. in History and a secondary in English Literature from Harvard University.

About SHEPHERD Therapeutics
The mission of SHEPHERD Therapeutics is to cure rare cancers. Founded by a rare cancer patient, SHEPHERD is a life sciences company relentlessly focused on using deep disease understanding, development expertise, and unwavering commitment to save people dying of neglected rare cancers. Shepherd is changing the traditional economics and timeline of drug development, delivering better treatments faster for patients who previously had none. To join the mission or learn more, visit shepherd.bio.

###

SHEPHERD THERAPEUTICS APPOINTS CHIEF RESEARCH OFFICER AND CHIEF CREATIVE OFFICER

For Immediate Release

Contact:
Lacie Randall
Chief Creative Officer
lacie@shepherd.bio

SHEPHERD THERAPEUTICS APPOINTS CHIEF RESEARCH OFFICER AND CHIEF CREATIVE OFFICER
Life Sciences Company Expands Team

CAMBRIDGE, MA— December 14, 2016 — SHEPHERD Therapeutics, a life sciences company founded to cure rare cancers, today announced the appointments of Jamie Dempsey Barber, PhD and Lacie Randall to serve as Chief Research Officer and Chief Creative Officer, respectively. “The appointments of Jamie and Lacie add crucial value to SHEPHERD’s scientific projects and marketing strategy,” said SHEPHERD founder and CEO David Hysong. “Jamie and Lacie bring incredible dedication to the company along with considerable experience in their respective fields. I look forward to working with both of them to create a patient-oriented company that delivers dynamic therapies for rare cancers.”

“After meeting David and hearing his story, I became infected with his excitement and determination to fight for patients of rare cancers. Once I started digging into the state of research and really understanding how sparse the drug development for rare cancers is I realized how great an impact SHEPHERD could have for these neglected patients,” said Dr. Dempsey Barber. “My role at SHEPHERD includes all things cancer biology related, including working with our team to identify rare cancers and determine the best therapeutic path forward.”

“This position at SHEPHERD allows me to utilize my experience in both nonprofit and for-profit companies to tell a story that desperately needs telling: the story of millions of patients suffering from rare cancers,” said Ms. Randall. “I am passionate about using innovative design to communicate this story in a thoughtful, urgent way that stresses both the scope of the problem and the dignity of the individuals fighting rare cancer day to day.”

About Dr. Jamie Dempsey Barber
Before joining SHEPHERD, Dr. Dempsey Barber was the head teaching fellow for both molecular and cellular biology courses at Harvard. Additionally, she instructed “The Biology of Cancer,” a course taught through the Harvard Extension School. During her Ph.D. studies, Dr. Dempsey Barber worked in Dr. John Blenis’s lab, focusing on the mTOR signaling pathway and alternative splicing regulation. Previously, she spent two years as a post-baccalaureate fellow at the National Cancer Institute, where she studied in Dr. Jonathan Wiest’s laboratory, focusing on the MAP kinase MAP3K8. Dr. Dempsey Barber holds a B.S. from Austin Peay State University and a Ph.D. in cell biology from Harvard University.

About Lacie Randall
Prior to SHEPHERD, Ms. Randall has helped create multiple American Advertising Award-winning campaigns for both nonprofit and for-profit organizations. Working with Major League Baseball, the National Football League, Publix, and Hermès, Ms. Randall has developed an appreciation for innovative design and creative resourcing. Ms. Randall holds a B.A. in International Affairs and Communication from The Florida State University.

About SHEPHERD Therapeutics
The mission of SHEPHERD Therapeutics is to cure rare cancers. Founded by a rare cancer patient, SHEPHERD is a life sciences company relentlessly focused on using deep disease understanding, development expertise, and unwavering commitment to save people dying of neglected rare cancers. SHEPHERD is changing the traditional economics and timeline of drug development, delivering better treatments faster for patients who previously had none. To join the mission or learn more, visit shepherd.bio.

###

SHEPHERD THERAPEUTICS ANNOUNCES DR. JOHANNE KAPLAN AS CHIEF SCIENTIFIC OFFICER

For Immediate Release

Contact:
Abby Reiner
Chief Marketing Officer
abby@shepherd.bio

SHEPHERD THERAPEUTICS ANNOUNCES DR. JOHANNE KAPLAN AS CHIEF SCIENTIFIC OFFICER

Biotech Veteran Joins the Mission to Cure Rare Cancer

CAMBRIDGE, MA— December 14, 2016 — SHEPHERD Therapeutics, a life sciences company founded to cure rare cancers, today announced it has appointed Johanne Kaplan, PhD, to the position of Chief Scientific Officer. In this role, Dr. Kaplan will oversee and support SHEPHERD’s scientific programs. “The appointment of Dr. Kaplan is an exciting addition to the SHEPHERD team,” said CEO and founder David Hysong. “Dr. Kaplan brings an impressive skill set and wealth of experience to SHEPHERD and will substantively contribute to the planning and development of our project portfolio.”

“I am very excited to be joining the dynamic team at SHEPHERD and I look forward to helping execute on the inspiring mission of developing cures for rare cancers,” said Dr. Kaplan.

About Dr. Johanne Kaplan
Prior to Shepherd, Dr. Kaplan spent 24 years at Genzyme, most recently serving as Vice President of Research. In this position, Dr. Kaplan directed pioneering research leading to the implementation of multiple clinical trials in the fields of gene therapy, autoimmunity, and oncology. Dr. Kaplan also led Genzyme’s successful development of Lemtrada (alemtuzumab) and Aubagio (teriflunomide) for the treatment of relapsing-remitting multiple sclerosis. Her work has resulted in over 60 scientific publications and multiple patents. Dr. Kaplan holds a B.Sc. and a Ph.D. in Microbiology and Immunology from McGill University in Montreal, Canada and conducted post-doctoral studies at the Albert Einstein College of Medicine in New York.

About SHEPHERD Therapeutics
The mission of SHEPHERD Therapeutics is to cure rare cancers. Founded by a rare cancer patient, SHEPHERD is a life sciences company relentlessly focused on using deep disease understanding, development expertise, and unwavering commitment to save people dying of neglected rare cancers. SHEPHERD is changing the traditional economics and timeline of drug development, delivering better treatments faster for patients who previously had none. To join the mission or learn more, visit shepherd.bio.

###